{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.3","upperLimit":"46.8","value":"11.4"},{"groupId":"OG001","lowerLimit":"1.3","upperLimit":"42.8","value":"25.7"},{"groupId":"OG002","lowerLimit":"0.5","upperLimit":"33.4","value":"7.4"},{"groupId":"OG003","lowerLimit":"1.0","upperLimit":"35.7","value":"14.2"},{"comment":"Due to the lack of available data caused by censoring subjects in the MEDI3617 + carboplatin/paclitaxel cohorts for this endpoint, median overall survival was not calculable.","groupId":"OG004","lowerLimit":"1.9","upperLimit":"34.4","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"38"},{"groupId":"OG003","value":"13"},{"groupId":"OG004","value":"7"}],"units":"Participants"}],"description":"Overall survival is defined as the time from the start of treatment with MEDI3617 until death. For the participants who were alive at the end of study or lost to follow-up, overall survival was censored on the last date when participants were known to be alive. Overall survival was evaluated using the Kaplan-Meier method.","dispersionType":"Full Range","groups":[{"description":"Participants received MEDI3617 via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.","id":"OG000","title":"MEDI3617 SINGLE AGENT TOTAL"},{"description":"Participants received MEDI3617 with bevacizumab via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.","id":"OG001","title":"MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL"},{"description":"Participants received MEDI3617 with bevacizumab via IV infusion every 2 weeks (Q2W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 28 days.","id":"OG002","title":"MEDI3617 + BEVACIZUMAB Q2W TOTAL"},{"description":"Participants received MEDI3617 on Days 1 and 15 with paclitaxel on Days 1, 8, and 15 via IV infusion in each cycle until unacceptable toxicity, documented disease progression, or other reasons. Each cycle consists of 28 days.","id":"OG003","title":"MEDI3617 + PACLITAXEL TOTAL"},{"description":"Participants received MEDI3617 with carboplatin and paclitaxel on Day 1 via IV infusion in each cycle until unacceptable toxicity, documentation of disease progression, or other reasons. Each cycle consists of 21 days.","id":"OG004","title":"MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL"}],"paramType":"MEDIAN","populationDescription":"Safety population included all participants who received treatment with MEDI3617.","reportingStatus":"POSTED","timeFrame":"Time from the first dose of investigational product until death due to any cause","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}